Sunshine Heart Inc (NASDAQ:SSH) announced on Tuesday that it got unconditional authorization from the Food and Drug Administration to start its pivotal U.S. trial for its flagship C-Pulse Heart Assist System. Shares climbed 17 percent premarket to $7.74. As of Monday’s close, the stock was dropped 4.5 percent over the previous three months. Accordant to […]
